PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  1  
  
 
 
NON- INTERVENTIONAL  (NI) STUDY PROTOCOL  
PASS Information  
 
Title  Transthyretin Amyloidosis Outcomes 
Survey (THAOS): A Global, Multi-Center, 
Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene  Mutations or Wild -Type Transthyretin 
Amyloidosis  
Protocol  number  B3461001  
Protocol  version  identifier  Protocol  Amendment 5,  13 July 2020  
Date  of last version  of protocol  07 July 2015  
Active  substance  N07XX08 tafamidis  
Medicinal  product  tafamidis  
Product  reference  EU/1/11/717/001 -004 
Procedure  number  EMEA/H/C/002294/XX  
Marketing  Authorization  Holder  (MAH)  Pfizer  Europe  MA EEIG  
Joint  Post-Authorization  Safety  Study 
(PASS)  No 
Research  question and  objectives  The Transthyretin Amyloidosis Outcomes 
Survey (THAOS) is a longitudinal, observational survey open to all patients with transthyretin - amyloidosis and 
participants with transthyretin (TTR) gene mutations without a diagnosis of transthyretin amyloidosis (ATTR amyloidosis).  To date, limited data are 
available on the natural history of the hereditary and wild- type forms of the 
disease,  including the regional differences in 
disease  expression  by TTR  variants  and non- 

PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  2  
 This document contains confidential information belonging to Pfizer.  Except as otherwise agreed to in 
writing, by accepting or reviewing this document, you agree to hold this information in confidence and not 
copy  or disclose  it to others  (except  where  required  by applicable  law) or use it for unauthorized purposes.  In 
the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.   
 mutated  TTR,  and the genotypic -phenotypic 
relationship in ATTR amyloidosis.  
The principal aims of the outcome survey are to better  understand and characterize the 
natural history of the disease by studying a large and heterogeneous patient population.  
Country(ies  /Regions  of study   Argentina, Australia, Austria, Belgium, 
Brazil,  Bulgaria,  Canada, Cyprus, Denmark, 
France, Germany, Greece, Israel, Italy, 
Japan, Korea, Luxembourg, Macedonia, 
Malaysia, Mexico, Netherlands, People’s 
Republic of China, Portugal, Republic of 
China, Taiwan, Romania, Spain, Sweden, 
Switzerland, Turkey, United States  
Author  PPD  
Marketing  Authorisation Holder(s) 
 
Marketing  Authorisation  Holder(s)   Pfizer Europe MA EEIG 
Boulevard  de la Plaine  17 
1050 Bruxelles  
Belgium   
MAH  contact  person  PPD 
 
 
Work Telephone: PPD 
Mobile Telephone: PPD 
Email: PPD  
 
 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  3  
  
1. TABLE OF CONTENTS  
1. TABLE OF CONTENTS  ...................................................................................................... 3  
2. LIST OF ABBREVIATIONS  ............................................................................................... 6  
3. RESPONSIBLE PARTIES  ................................................................................................... 8  
4. ABSTRACT  .......................................................................................................................... 9  
5. AMENDMENTS  AND UPDATES  .................................................................................... 11 
6. MILESTONES  .................................................................................................................... 18 
7. RATIONALE AND BACKGROUND ............................................................................... 18 
7.1. Disease Background  ............................................................................................... 18 
7.2. Rationale for the Survey  ......................................................................................... 20 
7.3. Role  of THAOS  in the Tafamidis  European Union Post-Marketing  
Commitment ............................................................................................................. 21 
8. RESEARCH  QUESTION AND OBJECTIVES  ................................................................. 21 
9. RESEARCH  METHODS  .................................................................................................... 22 
9.1. Study Design  ........................................................................................................... 22 
9.1.1. Study Treatment and  Duration  ................................................................... 23 
9.2. Setting  ..................................................................................................................... 23 
9.2.1. Inclusion Criteria  ........................................................................................ 23 
9.2.2. Exclusion Criteria  ...................................................................................... 24 
9.2.3. Genotyping  ................................................................................................. 24  
9.3. Variables  ................................................................................................................. 24 
9.3.1. Study Assessments  ..................................................................................... 24 
9.3.2. Safety Assessments  .................................................................................... 25 
9.3.3. Eligibility/Baseline  Visit ............................................................................ 26 
9.3.4. Return Visit ................................................................................................ 26 
9.3.5. Retrospective  Visit  ..................................................................................... 27 
9.3.6. Final  Visit ................................................................................................... 27 
9.4. Data  Sources  ........................................................................................................... 27 
9.5. Study Size ............................................................................................................... 27 
9.6. Data Management  ................................................................................................... 27 
9.6.1. Case Report Forms  (CRFs)/Data  Collection  Tools (DCTs)/Electronic  
Data  Record  ..................................................................................................... 27 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  4  
 9.6.2. Record  Retention  ........................................................................................ 28 
9.7. Data  Analysis  .......................................................................................................... 29 
9.7.1. Statistical Methods  ..................................................................................... 29 
9.7.2. Data  Summaries  ......................................................................................... 29 
9.7.3. Scientific  Board  .......................................................................................... 29 
9.7.4. Interim Analyses  ........................................................................................ 30 
9.8. Quality  Control  ....................................................................................................... 30 
9.8.1. Data  Editing  ............................................................................................... 30 
9.8.2. Audits  ......................................................................................................... 30 
9.8.3. THAOS  Electronic  Clinical  Database  ........................................................ 30 
9.9. Limitations  of the Research  Methods  ..................................................................... 30 
9.10. Other  Aspects ........................................................................................................ 31 
10. PROTECTION OF HUMAN  SUBJECTS  ........................................................................ 31 
10.1. Patient Information  ............................................................................................... 31 
10.2. Patient Consent  ..................................................................................................... 31 
10.2.1. Participation  in Investigational Clinical Trials  ........................................ 32 
10.3. Patient Withdrawal  ............................................................................................... 33 
10.4. Institutional Review  Board  (IRB)/Independent Ethics  Committee  (IEC) ............ 33 
10.5. Ethical Conduct of the Study  ................................................................................ 33 
11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE  
REACTIONS  FOR TAFAMIDIS -TREATED  SUBJECTS ............................................... 34 
11.1. Requirements  ........................................................................................................ 34 
11.2. Reporting Period  ................................................................................................... 35 
11.3. Causality  Assessment  ........................................................................................... 36 
11.4. Definitions  of Safety  Events  ................................................................................. 36 
11.4.1. Adverse Events  ........................................................................................ 36 
11.4.2. Abnormal Test Findings  ........................................................................... 37 
11.4.3. Serious Adverse Events  ........................................................................... 37 
11.5. Hospitalization  ...................................................................................................... 38 
11.6. Scenarios Necessitating  Reporting to Pfizer  Safety  within  24 Hours  .................. 39 
11.6.1. Exposure During Pregnancy  .................................................................... 39 
11.6.2. Exposure During Breastfeeding  ............................................................... 40 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  5  
 11.6.3. Medication  Error  ....................................................................................... 40 
11.6.4. Overdose, Misuse, Extravasation  .............................................................. 41 
11.6.5. Lack of Efficacy  ........................................................................................ 41 
11.6.6. Occupational Exposure  ............................................................................. 41 
11.7. Single Reference Safety  Document  ....................................................................... 41 
12. PLANS  FOR  DISSEMINATING  AND COMMUNICATING STUDY  RESULTS ........ 41 
12.1. Communication and Publication of Study Results  ................................................ 41 
13. REFERENCES ................................................................................................................... 43 
14. LIST OF TABLES ............................................................................................................. 46 
15. LIST OF FIGURES  ............................................................................................................ 46 
ANNEX 1. LIST OF STAND- ALONE DOCUMENTS  ......................................................... 46 
ANNEX 2. ENCEPP  CHECKLIST FOR  STUDY  PROTOCOLS  .......................................... 46 
ANNEX 3. ADDITIONAL INFORMATION ......................................................................... 46 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  6  
 2. LIST OF ABBREVIATIONS  
 
Abbreviation  Definition  
AE Adverse  event  
ATTR  Amyloid  fibril  protein  derived  from  misfolded TTR 
ATTR  amyloidosis  Disease  resulting  from  deposition  of ATTR  
ATTR -CM Transthyretin  amyloid  cardiomyopathy  (formerly  TTR -CM, or 
Senile Systemic Amyloidosis)  
ATTRm  ATTR  due to a hereditary  mutation  
ATTR -PN Transthyretin  amyloid  polyneuropathy  (formerly  TTR -FAP)  
ATTRwt  ATTR  due to wild type mutation  
CHMP  Committee  for Medicinal  Products  for Human  Use 
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CRF Case  Report  Form  
CSR Clinical study  agreement  
DCTs  Data collection tools  
EDP Exposure During Pregnancy  
EMA  European  Medicines Agency  
EMEA  European Medicines Evaluation Agency  
 ENCePP   European  Network  of Centres  for Pharmacoepidemiology  and 
Pharmacovigilance  
CCI     
EU European  Union  
EU-CHMP  European  Union  Committee  for Medicinal  Products  for Human 
Use 
FAC  Familial  Amyloid  Cardiomyopathy  
FAP Familial  Amyloid  Polyneuropathy  
FDA  Food  and Drug  Administration  
GFR  Glomerular Filtration Rate 
GPP Good  Pharmacoepidemiology  Practices  
ICH International Conference on Harmonization  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  7  
  
Abbreviation  Definition  
IRB/IEC  Institutional  Review  Board  /Independent  Ethics  Committee  
ISPE  International  Society  for Pharmacoepidemiology  
 ISPOR    International  Society  for Pharmacoeconomics  and Outcomes 
Research  
CCI     
NI Non-interventional  
 NIS AEM    Non-Interventional  Study  Adverse  Event  Monitoring  
CCI     
      
PhRMA  Pharmaceutical  Research  and Manufacturers  Association  
PASS  Post-Authorization  Safety  Study  
PI Principal Investigator  
QoL Quality  of life 
RMP  European  Medicines  Agency  Risk Management  Plan 
SAE Serious  Adverse  Event  
SAP Statistical  Analysis  Plan 
SSA Senile  Systemic  Amyloidosis  
TESPO  Tafamidis Enhanced Surveillance for Pregnancy  Outcomes  
THAOS  Transthyretin  Amyloidosis  Outcomes  Survey  
TTR Transthyretin  
TTR-CM Transthyretin  cardiomyopathy  (now  ATTR -CM) 
TTR-FAP Transthyretin  familial  amyloid  polyneuropathy  (now  ATTR -PN) 
US United  States  
UTI Urinary  Tract Infection  
Val30Met  Substitution  of methionine  for valine  at position  30 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  8  
  
3. RESPONSIBLE PARTIES  
Principal  Investigator(s)  of the Protocol  
The contact details for the Principal Investigators in the Transthyretin Amyloidosis 
Outcomes Survey (THAOS) are available upon request. 
Country  Coordinating  Investigators  
The contact details for the Principal Investigators who serve as the Country Coordinating 
Investigators in the Transthyretin  Amyloidosis Outcomes Survey (THAOS)  are available 
upon request. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  9  
 4. ABSTRACT 
Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi -C enter, 
Longitudinal,  Observational Survey  of Patients  With  Documented Transthyretin  Gene 
Mutations or Wild -Type Transthyretin Amyloidosis (Amendment 5; 13  July 2020, 
PPD  ) 
RATIONALE AND BACKGROUND: Transthyretin (TTR) amyloidosis is a rare disease 
c
aused by dissociation of the transthyretin tetramer into monomers, which misfold, 
ultimately  forming  amyloid  deposits in various organs. This structural instability  of the TTR 
tetramer can occur due to genetic mutations of the gene encoding the TTR protein or can be associated with aging.  There are over 120 known mutations of TTR gene, which result in 
variable phenotypic expressions of amyloidosis that commonly affect the peripheral nerves, heart, kidney or eye. 
The Transthyretin  Amyloidosis Outcomes Survey  (THAOS)  is a longitudinal, observational 
survey open to all patients with TTR gene mutations without a diagnosis of ATTR 
amyloidosis  and to patients diagnosed with ATTR amyloidosis (inclusive  of ATTR -PN and 
ATTR -CM).  To date, limited data are available on the natural history of the hereditary 
(ATTRm)  and wild-type (ATTRwt)  forms  of the disease, including the regional differences 
in disease  expression  by TTR  variants and non- mutated  TTR,  and the genotypic-phenotypic 
relationship in ATTR amyloidosis.  
The principal aims of the outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogeneous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to 
inform and educate clinicians about the management of this disease.  
The survey can also generate descriptive safety  summaries  using adverse and serious adverse 
event (AE/SAE) data in tafamidis -treated participants.  
RESEARCH  QUESTION AND OBJECTIVES:  The objectives of THAOS  are to describe 
the population of patients  affected  with ATTR  amyloidosis and to enhance  the understanding 
of the disease natural history, including the variability and progression of the hereditary and acquired forms of disease.  
STUDY DESIGN: THAOS is a non -interventional, global, multi- center, longitudinal 
observational survey open to all patients with ATTR amyloidosis, including both inherited and wild- type forms of disease, and participants with TTR gene mutations without disease 
diagnosis. There is no set number of patients  who will be enrolled.  The study has been open 
since 2007 and will continue until Pfizer declares the study complete (currently estimated to be the year 2023) or as long as patients  are able to participate,  or until they withdraw  consent.  
THAOS does  not involve the administration  of an investigational agent or other intervention. 
Patients  will continue to receive their current medications and all other standard care for their 
disease.  It is recommended that patient assessments be conducted at least annually and be 
recorded in the THAOS electronic data record close to the time they are performed.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  10  
 Treatment  with tafamidis  or with other  disease  modifying  therapies will be according to the 
product label with commercially available product or according to protocol- specified 
requirements if a participant is enrolled in a tafamidis interventional study.  
In addition to routine procedures for standard of care,  patients  will be asked  to complete 
patient outcome questionnaires at least annually; these are optional and do not affect a 
patient’s eligibility to participate in the survey.  
The survey will be conducted at sites worldwide.  
POPULATION: The study population includes patients with confirmed hereditary or wild-type ATTR  amyloidosis and those  with TTR  gene mutation  without a diagnosis of 
ATTR amyloidosis. 
VARIABLES: A series of assessments will be used to assess disease progression and the 
effects of tafamidis treatment including patient demographics, TTR genetic test results, family disease history, medical history, annual medical assessment, general examination, concomitant medications, hospitalizations, transplant history and complications, AE/SAE reporting for tafamidis -treated  subjects,  events of interest,  clinical  laboratory  data,  urinalysis, 
cardiovascular assessments, neurologic assessments, eye examination, body composition,  
 
DATA SOURCES: A computer -based application will be used for entering data into the 
THAOS electronic data record, allowing sites to enter data remotely through locally secured connections. The THAOS electronic data record allows for data to be recorded from an 
eligibility/baseline visit, at return visits, and in the form of status updates if the patient has  
not visited  the site. In addition, THAOS  physicians have the option of recording pre- baseline 
retrospective patient data.  Final data entry (the entry of a status update indicating that the 
patient  has been  discontinued) will occur when the survey is completed, if the patient dies, or 
elects to discontinue the survey. 
STUDY SIZE:  There  is no pre- determined  number of enrolled patients  or participating  sites 
in THAOS.  
DATA ANALYSIS:  Analysis of clinical  outcomes will be conducted on all enrolled  patients 
with available data.  Outcomes will be examined for the entire patient group, as well as 
through stratification of important variables that may affect outcomes (for example, but not 
limited to, TTR data, age, race, gender, country of origin). Outcomes will include results of 
the key clinical, functional and Patient Reported Outcome assessments used to define progression of disease . 
MILESTONES: Safety  data required as part of the European Medicines Agency Risk 
Management  Plan  (RMP)  for tafamidis  will be analyzed  annually for  submission  to the 
relevant regulatory authorities.  
 
and patient  death.  
CCI 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  11  
 5. AMENDMENTS  AND  UPDATES  
 
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
1 31-Jul- 
2007  Substantial  All Update  disease  terms 
and abbreviation 
nomenclature. New 
term hereditary transthyretin 
amyloidoses ATTR.  
ATTR -PN, ATTR - 
CM. Update  disease  terms  and 
abbreviation 
nomenclature. New term 
hereditary transthyretin amyloidoses ATTR. 
ATTR -PN, ATTR -CM.  
2 20-Jan- 
2010  Substantial  All Clarify that a patient 
may participate in THAOS if enrolled in 
an open- label or 
double-blind clinical  
trial. Clarify  that a patient  may 
participate in THAOS if enrolled in an open-label 
or double -blind clinical 
trial. 
3 30-Sep- 
2011  Substantial  All Addition of Pfizer 
safety language for adverse event and 
serious adverse event 
collection. Addition of 
safety data collection. Change of sponsor to  
Pfizer  INC.  Addition of Pfizer safety 
language for adverse event and serious adverse event 
collection. Addition of 
safety data collection.  
Change of sponsor to 
Pfizer INC.  
4 07–Jul- Substantial  All Significant protocol  The proposed protocol has 
 2015    reformatting according  been  reformatted  according  
    to the requirements  for to the requirements  for 
    non-interventional post- non-interventional  
    authorization  safety  post-authorization  safety  
    study (PASS) protocols  study (PASS) protocols as 
    and alignment  with specified in the European  
    appropriate guidance  Medicine  Agency’s  (EMA)  
    documents.  Guideline on Good  
     Pharmacovigilance  
     Practices:  Module  VIII 
     – Post-Authorisation  Safety  
     Studies (PASS) and 
     Guidance  for the Format  
     and Content of the Protocol  
     of Non -Interventional  Post- 
     Authorisation  Safety  
     Studies.  This has resulted  
     in the addition  of several  
     sections  including  PASS  
     information,  MAH  
     information,  Responsible  
     Parties,  Abstract,  and 
     Milestones.  Changes  were 
     made  to the Research  
     Methods section to adhere  
     to this format.  
   Section 6.0 Section 6.0 Rationale  Section updated to include  
Rationale and and Background  information  for marketing  
Background  updated to include  approval  of tafamidis  for 
 information  for treatment  of ATTR  in adult  
 marketing  approval  of patients  with Stage  1 
 tafamidis  for treatment  symptomatic  
 of ATTR  in adult  polyneuropathy  to delay  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  12  
  
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
    patients with Stage 1 
symptomatic 
polyneuropathy to delay 
peripheral neurologic impairment.  peripheral  neurologic 
impairment.  
   Section 8.1 
Study Design;  
8.4 Data 
Sources  Language revised to 
include the ability to record data in the form 
of status updates for 
those subjects that have 
not visited the site.  Language revised to  
include the ability  to record 
data in the form of status 
updates for those subjects 
that have not visited the 
site. 
   Section  8.2.1 
Inclusion Criteria  Inclusion Criteria 3 
modified to allow identification  of cardiac 
involvement by echocardiogram.  Inclusion Criteria 3 
modified to allow identification  of cardiac 
involvement by echocardiogram.  
  Inclusion Criteria #3: 
Confirmed genotyped TTR 
mutation with or without a 
diagnosis of ATTR, or 
wild-type TTR 
amyloidosis. Confirmation of wild-type TTR 
amyloidosis will be 
determined by genotyped 
confirmation that patient 
does not possess a known mutation in TTR gene  
(ie, is a carrier of wild-type allele only) via genetic 
testing and one of the 
following set of criteria: 
Evidence of cardiac 
involvement by 
echocardiogram as defined 
by mean left ventricle wall 
thickness of >12 mm, and 
presence of amyloid in 
cardiac biopsy tissue 
confirmed as TTR amyloid 
by mass spectrometry or; or 
evidence of cardiac involvement by 
echocardiogram as defined 
by mean left ventricle wall 
thickness of >12 mm, and 
presence of amyloid in non- 
cardiac tissue confirmed as TTR amyloid by mass 
spectrometry or 
immunohistochemistr y or 
evidence of cardiac involvement by 
echocardiogram as defined  
by mean  left ventricle  wall 
thickness of >12 mm, no  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  13  
  
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
     evidence of primary (light 
chain) amyloidosis, and 
presence of amyloid in 
cardiac tissue indirectly 
confirmed by scintigraphy 
with a ‘bone seeking tracer’ 
eg, 99mTC -DPD  
[99Mtc -3,3- 
diphosphono- 1,2-propano- 
dicarboxylic acid], 
99mTC -PYP 
[Pyrophosphate], and 
99mTC -HMDP 
[hydroxymethylene diphosphonate] with 
Perugini grade ≥ 2. 
   Section 
8.10.1.3  
Safety and 
efficacy in 
patients with 
TTR FAP  
mutations other than 
V30M  Section  8.10.1.3  Safety 
and efficacy  in patients 
with TTR FAP 
mutations other than 
V30M added.  Section  8.10.1.3  Safety  and 
efficacy in patients with TTR FAP mutations other 
than V30M added.  
   Section 9.1.1 
Participation 
in 
Investigationa l Clinical 
Trials  Section 9.1.1 
Participation in 
Investigational Clinical 
Trials language revised 
to specify that there  will 
be no reconciliation between databases and 
to allow for data entry 
for clinical trial data  
that was collected during the clinical trial 
study.  Section 9.1.1 Participation 
in Investigational Clinical 
Trials language revised to 
specify that there  will be no 
reconciliation between databases and to allow for 
data entry for clinical trial 
data that was collected 
during the clinical trial 
study. Revision: Data 
collected during the course of the clinical trial may be 
entered retrospectively at 
the end of the trial if the 
THAOS principal 
investigator obtains and 
documents approval from 
the study sponsor who 
conducted the clinical trial. 
Retrospective data entry 
cannot occur  until the study 
has been unblinded, which will permit identification  of 
the treatment received during the trial.  No 
reconciliation between databases will occur.  For 
interventional clinical  trials 
that include open-label 
tafamidis or other open- 
label investigational 
products,  patients  may 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  14  
  
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
     continue in THAOS, with 
the approval of the  
Sponsor, but AE data 
collection  will be addressed 
through the interventional clinical trial sponsor.  The 
THAOS principal investigator is responsible 
for obtaining and 
documenting approval from 
the study sponsor for  
investigational agents other 
than tafamidis.  
   Section 10 
Management 
and Reporting 
of Adverse 
Events/Adver 
se Reactions 
for 
Tafamidis -Tre 
ated Subjects  Language regarding 
reporting of overdose, 
misuse, extravasation 
and occupational 
exposure within  
24 hours was added.  Language regarding 
reporting of overdose, misuse, extravasation and 
occupational exposure 
within  24 hours was added 
to align  with current safety 
reporting practices.  This 
was previously included in 
Administrative Update  
dated 06June2014.  
   Section  10.7 
Single 
Reference 
Safety 
Document  Single  Reference  Safety 
Document identified.  Single  Reference  Safety 
Document identified.  
Added, “The  Product Label 
should continue to be used by the investigator for 
prescribing purposes and 
guidance.” This was 
previously included in Administrative Update  
dated 12December2013.  
5 17 
January 
2020 and 
including 
updates  
to reflect EMA  
requests 13July20 
20 Substantial  Throughout 
document  The Table of Contents 
section has now been captured with a page 
number in the Table of 
Contents, thus causing 
each section to be 
numbered 1 digit higher 
in protocol amendment 5 when compared to  
protocol amendment 4. To conform to the new 
Pfizer  Non-Interventional 
Study protocol template.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  15  
  
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
   Throughout 
document  Nomenclature  updated:  
• from 
transthyretin -assoc 
iated amyloidosis 
to just transthyretin 
amyloidosis.  
 
• from Transthyretin 
(TTR) Mutations 
or Wild -Type  TTR 
Amyloidosis to Transthyretin 
(TTR) Gene 
Mutations or  
Wild -Type ATTR 
Amyloidosis.  
 
• from amyloidoses 
to amyloidosis.  
 
• from familial 
amyloid 
polyneuropathy 
(TTR -FAP) to  
transthyretin amyloid polyneuropathy 
(ATTR -PN). 
 
• from familial 
amyloid cardiomyopathy (FAC) to
 
transthyretin 
amyloid 
cardiomyopathy (ATTR -CM).  As the understanding of 
ATTR amyloidosis advances, naming 
conventions are evolving to 
become more accurate in their description of the 
disease.  
   Section 
formerly 6.1/new  
7.1 Disease  
Background  More  information  on 
ATTR -CM 
(cardiomyopathy) was 
added  To provide further 
information about clinical 
features of the pathology.  
   Section 
formerly 8.2.1/new 
9.2.1  
Inclusion Criteria  Evidence of cardiac 
involvement by 
echocardiogram as 
defined by mean left 
ventricle wall thickness 
of >12 mm was removed from the 
Inclusion Criteria for 
wild type patients with 
presence of TTR 
amyloid in cardiac 
tissue confirmed by a 
cardiac biopsy or 
scintigraphy.  Positive endomyocardial 
biopsy or bone scintigraphy with Perugini grade ≥2 are 
sufficient for identification 
of cardiac ATTR 
involvement.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  16  
  
Amendment 
Number  Date  Substantial  or 
Administrative 
Amendment  Protocol  
Section(s) 
Changed  Summary of 
Amendment(s)  Reason  
   Section 9.2 A footnote  was added  to 
Table 1:  
The following 
important identified 
risks (Urinary tract 
infections, Diarrhea, 
Upper abdominal pain 
and Vaginal infections); 
important potential risks 
(Hypersensitivity 
reactions); and missing 
information (Safety and 
efficacy in elderly 
patients and Longer- 
term safety) have been 
removed from the list of 
ongoing safety  concerns 
from the tafamidis EU 
RMP Update (v 9.3), 
approved on  
17 February 2020.  To clarify  the information 
in Table  1 was not aligned 
with the tafamidus EU RMP Update (v 9.3), 
approved on 17 February 
2020.  
   Section 
formerly  
8.6/new 9.6 
Data 
Management  The text has been 
updated with the latest 
Pfizer  protocol template 
language.  To conform to the new 
Pfizer  Non-Interventional 
Study protocol template.  
   Section 
formerly  
8.7/new 9.7. 
Data  Analysis  The text has been 
updated with the latest Pfizer  protocol template 
language.  To conform to the new 
Pfizer  Non-Interventional 
Study protocol template.  
   Section 
formerly 8.8.1/new 
10 Data  
protection and patient  
identification.  Moved to Section 10. To conform to the new 
Pfizer  Non-Interventional 
Study protocol template.  
   Section 
formerly 
9/new  
10 Protection of Human 
Subjects.  Patient  Information  and 
Consent split into 
2 sub-sections.  The text 
has been updated with 
the latest Pfizer  
protocol template 
language.  To conform to the new 
Pfizer  Non-Interventional 
Study protocol template.  
   Section 
formerly 8.10/ new 9.10 
Other  
Aspects.  Sub-category 
“Important Missing 
Data”  removed and 
“Not Applicable”  
added.  This was duplicative  of the 
text captured in Table 1.  
   Section 
formerly 
10/new 11 
Management 
and Reporting 
of Adverse 
events.  Removed  requirement 
to report Pregnancy of 
Partner.  As tafamidis has been 
shown not to be present in seminal fluid and therefore 
male contraception is not 
required in the approved 
Product Information, 
collection of data regarding  
the pregnant  partner  of the 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  17  
  
 
CCI 
 Annex  
male  recipient  of tafamidis 
is not needed.  
Reason  
 Summary of 
Amendment(s)  
Protocol 
Section(s) 
Changed  
Substantial or 
Administrative 
Amendment  
Date  
 Amendment 
Number  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  18  
  
6. MILESTONES  
 
Milestone  Planned  date 
Start  of data collection  (First  Subject  First Visit:  FSFV)  16 December  2007  
End of data collection  (Last  Subject  Last Visit:  LSLV)  16 June 2023  
Study  progress  report  Study  progress  reports  are submitted  to 
the EMA annually  
Final  study  report  16 May 2024  
 
7. RATIONALE AND BACKGROUND  
7.1. Disease Background  
Transthyretin  (TTR)  a 127- amino  acid,  tetrameric  protein, primarily  synthesized  in the liver, 
is a secreted  protein  present in the blood and cerebrospinal fluid  and is a carrier  of thyroxine 
and retinol-binding protein- retinol (vitamin A) complex.  Transthyretin amyloidosis (ATTR 
amyloidosis) is a rare disease caused by destabilization and dissociation of the native TTR 
tetramer into monomers, which  can result  in misfolding  and the formation  of amyloid  fibrils 
in various organs in amounts sufficient to impair normal functioning.1-5 
The 2 major phenotypes which form the spectrum of ATTR amyloidosis are transthyretin amyloid polyneuropathy (ATTR- PN), formerly referred to as transthyretin familial amyloid 
polyneuropathy (TTR-FAP), which primarily affects the peripheral and autonomic nerves, and transthyretin amyloid cardiomyopathy (ATTR- CM) which primarily affects the 
myocardium. These clinical  manifestations  may occur  in isolation  or together. Both  result  in 
progressively impaired function, and ultimately in death. 
There  are over  130 known mutations  of TTR  gene,
4 which  result in  variable  phenotypic 
expressions of amyloidosis  that commonly affect  the peripheral nerves,  heart,  kidney or 
eye.6,7 
ATTR -PN 
The hereditary forms of ATTR amyloidosis are autosomal dominantly inherited diseases8,9 
with a variable penetrance that can affect multiple generations in a family and have a 
substantial impact on patients and their families.  Val30Met (substitution of methionine for 
valine at position 30) is the most common mutation associated with ATTR -PN, with 
symptom onset  usually  in the third  to fourth  decade of life, depending on the mutation  carried 
and the patient’s ethnic background.6-11 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  19  
 The main feature of ATTR -PN is progressive sensorimotor and autonomic neuropathy. 
Sensory neuropathy typically  starts  in the lower  extremities  followed by motor neuropathy 
within a few years.8,10,11 Autonomic neuropathy quite often accompanies the sensory and 
motor deficits.12 ATTR -PN is more frequently observed in certain areas of Portugal, 
Sweden, and Japan but has been identified throughout the world.11 Although penetrance 
varies greatly among geographic and ethnic foci, the outcome of the disease is invariably 
progressive and fatal.  The lifespan  for patients is severely  shortened, with death  occurring 
within a mean of 10- 15 years from the first symptoms.14,1 
Disease- modifying therapies for ATTR -PN include TTR stabilizer tafamidis,30 orthotopic 
liver transplantation,13-15 RNA interference (RNAi)-based drugs, and transthyretin- directed 
antisense oligonucleotide drugs. Tafamidis  meglumine was approved in the European Union 
(EU) on 16 November 2011 for the treatment of ATTR in adult patients with Stage 1 
symptomatic polyneuropathy to delay peripheral neurologic impairment.  Currently, it is 
approved for ATTR-PN in over 40 countries worldwide. Subsequently, Tegsedi (inotersen) and Onpattro (patisiran) for the treatment of hereditary ATTR amyloidosis in patients with polyneuropathy (ATTR-PN) have also been approved in the EU and US.
16-18 
Tafamidis is a novel specific stabilizer of both tetrameric wild -type (w-t) TTR and of 
amyloidogenic variants of TTR (ATTR). By binding to the native tetrameric form of TTR, 
tafamidis  inhibits tetramer dissociation, the rate limiting step in the formation of TTR 
amyloid.  By inhibiting TTR amyloid formation, this novel class of TTR stabilizer drug has 
the potential to disrupt the progression of ATTR.  The specificity  of the binding to TTR  also 
limits tafamidis  to the treatment of ATTR amyloidosis only, with no activity anticipated for 
other types of amyloidosis.  Tafamidis slows the progression of disease and therefore 
represents a disease modifying therapy.  
ATTR -CM 
ATTR -CM occurs when  the amyloid  fibrils  infiltrate  the myocardium,  leading to diastolic 
dysfunction progressing to, heart failure, restrictive cardiomyopathy, and death.19 
ATTR -CM, also known as familial amyloid cardiomyopathy (FAC), is a late- onset disease 
with symptoms typically occurring in patients over 60 years old.20 This disease can be 
inherited  as an autosomal dominant trait caused  by mutation  in the TTR  gene (commonly  the 
Val122Ile mutation which occurs with high frequency [prevalence of 3.9%]22 in 
African -Americans);  however, a mutation  in TTR  gene is not a pre- requisite  for developing 
ATTR -CM. In the elderly, wild -type (normal) TTR may become structurally unstable 
resulting in deposition of amyloid fibrils primarily in heart tissue and leading to restrictive cardiomyopathy and heart failure.
21 
Wild -type ATTR amyloidosis (previously known as senile systemic amyloidosis (SSA) or 
senile cardiac amyloidosis,23-27 is diagnosed based on positive bone scintigraphy21,29 
(Perugini grade ≥2)30 or confirmed ATTR amyloid by tissue biopsy and 
immunohistochemical staining, and characteristic echocardiographic abnormalities21,29 in the 
absence of a TTR gene mutation and a plasma cell dyscrasia.  The clinical presentation of 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  20  
 wild-type ATTR  amyloidosis is similar  to variant  ATTR- CM, with the disease primarily 
affecting elderly males.20 
Combined heart  and liver transplantation is a treatment option for ATTR -CM, however is 
limited by organ availability and significant patient co -morbidity.  
Tafamidis is currently the only approved treatment for ATTR -CM with approvals in a 
growing number of countries worldwide  including but not limited  to: Japan  (March  2019) for 
tafamidis  meglumine 80 mg daily  in patients  with wild-type and variant forms  of ATTR -CM; 
the US (May 2019) for tafamidis meglumine 80 mg daily and tafamidis 61mg daily for the 
treatment of the cardiomyopathy of wild -type or hereditary transthyretin -mediated 
amyloidosis in adults to reduce cardiovascular mortality and cardiovascular- related 
hospitalization; and the EU (February 2020) as a line extension to tafamidis 61 mg daily for 
the treatment of wild -type or hereditary transthyretin amyloidosis in adult patients with 
cardiomyopathy.  
This non-interventional study (disease registry), designated as a post- authorization safety 
study (PASS) is open to all patients with transthyretin (TTR) gene mutations without a diagnosis of ATTR  amyloidosis and to patients diagnosed with ATTR  amyloidosis (inclusive 
of ATTR -PN and ATTR-CM) in agreement with the European Medicine Agency (EMA) 
until 16 June 2023. 
7.2. Rationale for the Survey  
The Transthyretin  Amyloidosis Outcomes Survey  (THAOS)  is a longitudinal, observational 
survey open to all patients with TTR gene mutations without a diagnosis of ATTR 
amyloidosis  and to patients diagnosed with ATTR amyloidosis (inclusive  of ATTR -PN and 
ATTR -CM).  To date, limited data are available on the natural history of the hereditary 
(ATTRm)  and wild-type (ATTRwt)  forms of the disease, including the regional differences 
in disease  expression  by TTR  variants and non- mutated  TTR,  and the genotypic-phenotypic 
relationship in ATTR amyloidosis.  
The principal aims of the outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogeneous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to 
inform and educate clinicians about the management of this disease.  
The survey can also generate descriptive safety  summaries  using adverse and serious adverse 
event (AE/SAE) data in tafamidis -treated participants.  All AE/SAE data will be collected 
and summarized, including (but not limited to) the safety concerns detailed in Table 1 , 
Summary of Safety Concerns to be Assessed in THAOS.  
AE/SAE  data collection  in THAOS  will be utilized  in the post- marketing  setting  to provide 
additional information on the safety of tafamidis over the long term as well as its effect on survival.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  21  
 Limited data was collected in ATTR -CM studies with tafamidis in patients with New York 
Heart  Association  (NYHA)  class IV, and it is expected  that THAOS  will provide additional 
information on the safety and efficacy of tafamidis in this population. Safety data will be 
collected through THAOS for all participants treated with tafamidis.  
Additional data corresponding to the events of interest  detailed  in Table  1 Summary  of Safety 
Concerns to be Assessed in THAOS will also be collected for all THAOS participants 
(tafamidis -treated and participants not treated with tafamidis).  The purpose of the additional 
data collection is to further characterize the natural history of disease amongst untreated participants and, as applicable, to gather data to provide context for safety events observed amongst tafamidis -treated participants.  
7.3. Role  of THAOS  in the Tafamidis  European Union  Post-Marketing  Commitment 
On 21 July 2011 the European Union (EU) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product tafamidis 20  mg capsule intended for the treatment of 
ATTR amyloidosis in adult patients with Stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.  Granting of marketing authorization for tafamidis was 
made under exceptional circumstances.  The collection of safety data in THAOS will fulfill 
part of the post- marketing commitment to the CHMP for tafamidis.  This non- interventional 
(NI) study is designated  as a Post-Authorisation Safety  Study (PASS)  and is a commitment to 
the EMA.  Additionally, data in ATTR- CM patients collected via this registry will further 
characterize important potential risks and missing information with tafamidis (see Section 8) as agreed with the EMA during the line extension procedure for ATTR- CM. 
8. RESEARCH  QUESTION AND OBJECTIVES  
The objectives of THAOS  are to: 
• Describe the population of patients  affected  with ATTR  amyloidosis;  
• Enhance the understanding of disease  natural  history,  including the variability  and 
progression of the hereditary and acquired forms of the disease; 
• Better  understand the genotype – phenotype relationship  in ATTRm.;  
• Compare the progression of disease and overall survival in patients  with ATTR  with 
and without liver transplant; 
• Foster  an international community of medical  experts who will develop 
recommendations on the clinical management of ATTR amyloidosis;  
• Provide information  to better understand the management  and treatment of patients 
with ATTR amyloidosis through publication of the survey data; 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  22  
 • For tafamidis -treated  participants,  collect  and summarize all AE/SAE  data,  including 
for the specific safety concerns outlined in Table 1  Summary of Safety Concerns to 
be Assessed in THAOS comprising important identified risks, important potential 
risks, and missing information that includes long -term safety in ATTR -CM patients 
with NYHA Class IV.  For those not treated with tafamidis, collect and summarize 
additional data on the events of interest listed in Table 1 . 
9. RESEARCH METHODS  
9.1. Study Design  
THAOS is a non -interventional, global, multi -center, longitudinal observational survey open 
to all patients with ATTR amyloidosis, including both inherited and wild- type forms of 
disease,  and participants  with TTR  gene mutations  without disease diagnosis. There  is no set 
number of patients who will be enrolled.  The study has been open since 2007 and will 
continue until Pfizer declares the study complete (currently estimated to be the year 2023).  
or as long as patients are able to participate, or until they withdraw consent.  
THAOS does  not involve the administration  of an investigational agent or other intervention. 
Patients  will continue to receive their current medications and all other standard care for their 
disease.  It is recommended that patient assessments be conducted at least annually and 
recorded in the THAOS electronic data record close to the time they are performed.  
Treatment  with tafamidis  or with other  disease modifying  therapies will be according to the 
product label with commercially available product or according to protocol- specified 
requirements if a participant is enrolled in a tafamidis interventional study.  
In addition to routine procedures for standard of care,  patients  will be asked  to complete 
patient outcome questionnaires at least annually; these are optional and do not affect a patient’s eligibility to participate in the survey.  
The THAOS  electronic  data record  allows  for data to be recorded from an eligibility/baseline 
visit, at return visits, and in the form of status updates if the patient has not visited the site.  
In addition, THAOS physicians have the option of recording pre- baseline retrospective 
patient  data.  Final  data entry  (the entry  of a status  update indicating that the patient  has been 
discontinued) will occur when the survey is completed, if the patient dies, or elects to discontinue the survey.  
Physicians at survey sites will evaluate patients to determine eligibility.  Each patient must 
review  and sign an informed  consent document before  any data are recorded  in the THAOS 
electronic  data record.  The date the informed  consent  form  is signed will be documented in 
the THAOS electronic data record.  
Data will be recorded from all patient visits and entered into the THAOS electronic data record as soon as possible after the visit is complete.  Data will be entered into a secure, 
confidential computer- based  application which  allows  for remote  data entry  through locally 
secured connections.  A Scientific Board representing the THAOS physicians will meet at 
least annually and recommend statistical analyses.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  23  
 Each  survey site will be required to obtain local  Institutional Review  Board  (IRB)/Ethics 
Committee (EC) approval to participate in THAOS and before enrolling patients.  
There  is no pre- determined  number of enrolled patients  or participating  sites in THAOS.  The 
survey will be conducted at sites worldwide. 
9.1.1. Study  Treatment  and Duration  
THAOS has been open since 2007. There is no set number of patients who will be enrolled 
in the survey. Patients will be enrolled from different countries around the world.  All 
patients  who take part in this survey  will be followed  until the survey is declared  complete by 
Pfizer (currently estimated to be the year 2023) or as long as they are able to participate, or until they  withdraw consent to participate. For those patients receiving tafamidis, the dosage 
recommendations (including dosage strength and timing of the dosing) should be based on the prescribing physician’s clinical judgment and the approved product label or open- label 
study protocol (for those patients  receiving  tafamidis  as part of their participation  in a clinical 
study).  
9.2. Setting  
The study population includes patients with confirmed  genotyped TTR  mutation  with or 
without a diagnosis of hereditary or wild -type ATTR amyloidosis. 
Assessments were proposed by  a team of experts as components of standard clinical practice 
for patients with ATTR amyloidosis and are recommended but are not required; the assessments to be performed  will be determined  by the investigator according to the patient’s 
individual care plan. Additional information on assessments is included in a separate 
THAOS Case Report Form Completion Guidelines which will be provided to each survey site. 
9.2.1. Inclusion Criteria  
Patients  must  meet  all of the following  inclusion criteria  to be eligible  for inclusion into 
THAOS:  
1. Evidence of a personally signed and dated  informed  consent document indicating  that 
the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.  
2. Males and females ≥18 years of age. 
3. Confirmed genotyped TTR mutation with or without a diagnosis of hereditary or 
wild-type ATTR amyloidosis. Confirmation of ATTRwt amyloidosis will be 
determined by genotyped confirmation that patient does not possess a known 
mutation  in TTR  gene (ie, is a carrier  of wild-type allele  only) via genetic testing  and 
one of the following set of criteria (a, b, or c ): 
a. Presence of amyloid  in cardiac biopsy tissue  confirmed  as TTR  amyloid  by mass 
spectrometry or immunohistochemistry; or  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  24  
 b. Evidence of cardiac involvement by echocardiogram  as defined  by left ventricle 
wall thickness of >12 mm, and presence of amyloid in non- cardiac tissue 
confirmed as TTR amyloid by mass spectrometry or immunohistochemistry; or  
c. No evidence of primary (light chain) amyloidosis, and presence of amyloid in 
cardiac tissue indirectly  confirmed  by scintigraphy with a “bone seeking  tracer” 
eg, 99mTC- DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid], 
99mTC- PYP [Pyrophosphate], and 99mTC -HMDP [hydroxymethylene 
diphosphonate] with Perugini grade ≥2. 
9.2.2. Exclusion Criteria  
Patients  meeting  any of the following will not be included in the study:  
1. Patient has primary  or secondary amyloidosis.  
9.2.3. Genotyping  
TTR genotyping is required to confirm patient eligibility and will be performed before the Eligibility/Baseline visit and outside of the auspices of the survey according to the site’s standard  practices.  For patients  with a documented TTR  gene mutation,  the mutation(s) will 
be recorded in the patient’s medical record and in the electronic data record.  
9.3. Variables  
The objectives of THAOS are to describe the population of patients affected with ATTR amyloidosis  and to enhance the understanding of the disease  natural history, including the 
variability and progression of the hereditary and acquired forms of disease. 
All visits are intended to be outpatient visits.  Assessments are recommended but not 
required and will be determined by the investigator.  All assessments that occur will be 
recorded in the THAOS electronic data record.  The THAOS Electronic Case Report Form 
Completion Guidelines detail  how the data for these assessments should be entered  into the 
electronic data record.  Blank worksheets and QoL questionnaires (available in patient’s 
native language) are available to download from the THAOS electronic data record. 9.3.1. Study Assessments  
• Written informed consent/assent.  
• Inclusion/exclusion criteria.  
• Patient  demographics (year  of birth, gender, ethnic  origin, race (if allowed  by local 
regulations).  
• TTR  genetic test results.  
• Family  disease history  (previous family  history  of ATTR amyloidosis).  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  25  
 • Medical  history (past and  current signs, symptoms,  and medical diagnoses). 
• Annual medical  assessment  (current signs and symptoms).  
• General  examination  (weight/height,  vital signs,  CCI  
• Concomitant medications (category, indication, start and stop dates).  
• Hospitalizations (admission  and discharge dates,  reason  for hospitalization).  
• Transplant  history  and complications (date(s) of transplant(s),  organ(s) transplanted, 
information on complications).  
• AE/SAE  reporting  for tafamidis -treated  subjects.  
• Events of interest  (as listed  in Table  1, Summary  of Safety  Concerns to be Assessed 
in THAOS).  
• Clinical laboratory  data (hematology, clinical chemistry,  liver function tests,  thyroid 
function tests). 
• Urinalysis  (includes glomerular filtration  rate [GFR]).  
• Cardiovascular  assessments (electrocardiogram,  echocardiogram, Holter  monitoring,  
CCI  
• Neurologic assessments (deep  tendon reflexes,  sensation  [pinprick, soft touch, 
vibration, and position sense], motor strength, nerve conduction studies). 
• Eye examination (intraocular pressure, vitreous,  presence of opacities).  
• Body composition (total bone mineral density and content, total lean and fat mass).  
•  
 
 
• Patient  death  (data  on patient  death  will be collected  independently of the visit 
schedule).  
9.3.2. Safety  Assessments  
AE/SAE data collected in THAOS will be used to further characterize the safety profile of 
tafamidis and as a result, to fulfill certain aspects of the EU post- marketing commitment for 
tafamidis.  Based  on the safety  concerns detailed  in Table  1, corresponding data for Events of 
Interest will be collected to characterize both the natural history of ATTR in participants not treated with tafamidis and safety concerns amongst tafamidis -treated patients.  
CCI 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  26  
  
Table  1. *Summary  of Safety  Concerns to be Assessed  in THAOS  
 
Important identified risks 
(Adverse Drug  Reactions)  Urinary  tract infection 
Diarrhea  
Vaginal infections  
Upper abdominal pain 
Important potential risks  Hepatotoxicity 
Hypersensitivity reactions  
Reproductive and developmental toxicity  and lactation  
Changes in thyroid function, particularly  in pregnant 
women  
Important missing 
information  Safety  and efficacy  in elderly  patients 
Longer term safety  
Safety  and efficacy  in patients  with ATTR -PN mutations 
other than Val30Met  
Patients with NYHA Class IV  
Patients  with severe hepatic impairment 
Note: *The  following  important  identified  risks  (Urinary  tract infections,  Diarrhea,  Upper  abdominal  pain 
and Vaginal infections); important potential risks (Hypersensitivity reactions); and missing information 
(Safety and efficacy in elderly patients and Longer -term safety) have been removed from the list of 
ongoing safety concerns from the tafamidis EU RMP Update (v 9.3), approved on 17 February 2020.  
 
 
All AE/SAE data will be collected for participants treated with commercially available 
tafamidis; participants receiving tafamidis as part of their participation in an open -label 
clinical study will have AE/SAE data collection through the open- label clinical study; 
reporting of other events in addition to the Events of Interest will be available for participants 
not treated with tafamidis.  
9.3.3. Eligibility/Baseline  Visit  
This visit will be performed to determine a patient’s eligibility.  It includes obtaining 
informed  consent,  chart  review  to determine  eligibility,  and recording results of study 
assessments as outlined in Section 9.3.1 Study Assessments.  
9.3.4. Return  Visit 
Return  visits  will, on average,  be conducted annually or more  frequently at the discretion  of 
the survey  physician. The reporting  window for collecting  changes in signs, symptoms, AE 
information, and new diagnoses is from the last prior visit.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  27  
 9.3.5. Retrospective Visit 
Any assessments listed in Section 9.3.1 Study Assessments and performed prior to the 
patient’s  Eligibility/Baseline  visit may be entered  into the THAOS  electronic  data record  as 
retrospective visit data.  This data collection is optional.  
9.3.6. Final Visit  
Final visit data collection, including  collection of AE/SAE  information,  will be performed  at 
the completion of the survey, or at the time a patient dies or elects to discontinue from the 
survey, whichever occurs first. If a patient dies while  enrolled  in the survey, the site is asked 
to collect all available information about the patient’s death and complete the final visit assessment and patient death case report forms in the THAOS electronic data record.  
9.4. Data  Sources  
The THAOS  electronic  data record  allows  for data to be recorded from an eligibility/baseline 
visit, at return visits, and in the form of status updates, if the patient has not visited the site.  
In addition, THAOS physicians have the option of recording pre- baseline retrospective 
patient  data.  Final  data entry  (the entry  of a status  update indicating that the patient  has been 
discontinued) will occur when the survey is completed, if the patient dies, or elects to discontinue the survey (refer to Section 9.3.6 above). 
9.5. Study  Size 
THAOS has been open since 2007. There is no set number of patients who will be enrolled 
in the survey. Patients will be enrolled from different countries around the world.  All 
patients  who take part in this survey  will be followed  until the survey is declared  complete by 
Pfizer (currently estimated to be the year 2023) or as long as they are able to participate, or until they withdraw consent to participate. 
9.6. Data  Management  
9.6.1. Case  Report  Forms  (CRFs)/Data  Collection  Tools (DCTs)/Electronic  Data  Record  
As used in this protocol the term CRF  should be understood to refer  to either  a paper form  or 
an electronic  data record  or both, depending on the data collection  method  used in this study.  
A computer- based  application  will be used for entering  data into the THAOS  electronic data 
record, allowing sites to enter data remotely through locally secured connections.  The 
computer- based application and the data to be collected and entered are described in the 
THAOS Case Report Form Completion Guidelines which will be provided to each site. 
A CRF is required and should be completed for each included patient. The completed 
original CRFs  are the sole property of Pfizer  and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory authorities, without written permission from Pfizer.  The investigator shall ensure that the 
CRFs are securely stored at the study site in encrypted electronic and will be password protected or secured in a locked room to prevent access by unauthorized third parties. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  28  
 The investigator has ultimate responsibility for the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRFs and any other data collection forms (source documents) and ensuring that they are accurate, authentic/original, attributable, complete, consistent, legible, timely (contemporaneous), enduring, and available when required.  The 
CRFs must be signed by the investigator or by an authorized staff member to attest that the data contained on the CRFs  are true. Any corrections  to entries  made in the CRFs  or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the original entry.  
In most cases the source documents are the hospital or the physician's chart.  In these cases, 
data collected on the CRFs must match those charts.  
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator  site and at Pfizer that clearly  identifies  those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document. 
Prior to initiating  the survey, the Sponsor or its designee will train the THAOS  physician and 
site staff to use the THAOS  electronic data record  and review  the THAOS Case  Report Form 
Completion Guidelines. Ongoing technical support will be provided to survey sites by a 
database development company. 
9.6.2. Record  Retention  
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all participating patients (sufficient information to link records, eg, CRFs and hospital records), all original signed informed consent documents, copies of all CRFs, safety reporting forms. source documents, detailed records of treatment disposition, and adequate documentation of relevant correspondence (eg, letters,  meeting  minutes, and telephone call reports).  The records should 
be retained by the investigator according to local regulations or as specified in the clinical study agreement (CSA), whichever is longer. The investigator must ensure that the records 
continue to be stored securely for so long as they are retained.  
If the investigator becomes unable for any reason  to continue to retain  study  records for the 
required period (eg, retirement, relocation), Pfizer should be prospectively notified. The 
study records must be transferred to a designee acceptable to Pfizer, such as another investigator, another institution, or to an independent third party arranged by Pfizer. 
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required  by applicable local  regulations. 
The investigator must obtain  Pfizer's  written  permission  before disposing of any records, 
even if retention requirements have been met.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  29  
 9.7. Data  Analysis  
9.7.1. Statistical Methods  
Detailed  methodology for summary  and statistical  analyses of data collected  in this study  will 
be documented in a statistical analysis plan (SAP), which will be dated, filed and maintained 
by the sponsor. The SAP may modify the plans outlined in the protocol; any major modifications of primary endpoint definitions or their analyses would be reflected in a protocol amendment. 
9.7.2. Data  Summaries  
THAOS  data will be available for analysis on 3 different levels:  by patient,  by individual 
survey site, and across survey sites.  
The primary objective of the survey is to better understand the natural history of ATTR 
(hereditary and wild -type forms) and the progression of disease in this patient population. 
Analysis of clinical  outcomes will be conducted on all enrolled patients  with available data. 
Outcomes will be examined for the entire patient group, as well as through stratification of important variables  that may affect  outcomes (for example,  but not limited  to, TTR  variant, 
age, race, gender, country of origin). Outcomes will include results of the key clinical, 
functional and QoL assessments used to define progression of disease.  
Data  will be summarized  descriptively  and modeled using appropriate  statistical 
methodology.  
THAOS physicians may use the THAOS electronic clinical database to obtain ongoing longitudinal data on their individual patients  to assist  them  in following and caring  for their 
patients.  A physician can extract their individual survey site data for an individual or all 
patients enrolled at the survey  site to identify  trends in the data and/or assist in patient care 
and monitoring at their survey site. 
THAOS physicians may request or share data across survey sites.  A request may pertain to 
available information on patients with a newly identified TTR variant, or on a subset of 
patients  to assist  a THAOS  physician with the clinical  management of a patient  (or patients), 
or to provide information pertinent to research interests across survey sites.  Requests for 
data should be forwarded to the Sponsor for processing and will be promptly reviewed. 
9.7.3. Scientific Board  
The Scientific  Board  is comprised  of a group of scientific and clinical experts in the field of 
amyloid disease who will provide scientific oversight and interpretation of the data 
originating  from  THAOS and its sub- studies.  The role of the Board  is to develop treatment 
recommendations and practice guidelines for patients with transthyretin amyloidosis based on findings from either the survey or external data. The roles and responsibilities of the Board are detailed in the THAOS Scientific Board Charter.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  30  
 9.7.4. Interim  Analyses  
There  is no formal interim analysis planned.  
Safety  data required as part of the European Medicines Agency RMP  for tafamidis  will be 
analyzed and submitted annually.  
One or more  data extracts will be performed annually in order  to support ad hoc analyses for 
publications and for pricing and reimbursement. 
9.8. Quality Control  
9.8.1. Data Editing  
Data entered into the THAOS electronic clinical database will be automatically checked 
according  to the database specifications,  focusing on data critical for analysis,  using limits  set 
within the programming. Error messages will appear notifying the sites of discrepancies as 
they are identified or at the point of data signature.  Data clarification requests may be 
generated and sent electronically to the THAOS sites.  Completed requests will be returned  
to the electronic clinical database.  All changes to the THAOS electronic clinical database 
will be tracked via an audit trail.  
9.8.2. Audits  
Local  or international regulatory  authorities,  the IRB/EC,  the Sponsor, or its designee,  may 
request access to all patient consent forms, source documents, THAOS electronic data records, and other survey documentation for on- site audit or inspection.  Direct access to 
these documents must be guaranteed by the investigator, who must provide support at all times for these activities.  
9.8.3. THAOS  Electronic Clinical Database  
The investigator has ultimate responsibility for the collection and reporting of all clinical, safety, and laboratory data entered in the THAOS electronic clinical database from source documents (eg, hospital or physician patient charts), physical examinations, and patient reports. The investigator must ensure that the information is accurate, authentic/original, 
attributable,  complete,  consistent,  timely  (contemporaneous), enduring, and available  when 
required.  
9.9. Limitations  of the Research  Methods  
The observational nature of this study has the potential to introduce selection or ascertainment bias.  The study population could be more heterogeneous. Confounding leads 
to biased  estimates  of associations  of risk factors  or treatment with outcome and thus impacts 
the validity of the conclusions from the study. Analytical methods (like matching, 
multivariate regression) would be used to control for confounding. 
Other potential limitations to the validity of the study include missing data and loss to 
follow -up or censoring. Appropriate statistical  methods would be employed to account  for 
missing data and described in the SAP. Sensitivity analysis to assess the impact of loss to 
follow -up will also be explored.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  31  
 9.10. Other  Aspects 
Not Applicable.  
10. PROTECTION OF HUMAN SUBJECTS  
10.1. Patient  Information  
All parties will comply with all applicable laws,  including laws regarding  the implementation 
of organizational and technical measures to ensure protection of patient personal data. Such 
measures will include omitting patient names or other directly identifiable data in any  
reports, publications, or other disclosures, except where required by applicable laws. 
Upon entry  into THAOS,  a patient will be assigned  a unique patient  number. This number is 
a combination of the site country identifier, the assigned site number, and the number given 
to a patient in order of enrollment at the site (eg, SE 01 005 is the fifth patient enrolled at the 
first participating site in Sweden).  Each patient will be identified by this unique number. In 
order to maintain patient privacy, all databases, survey reports, and communications will identify the patient only by the unique patient number. 
The personal data will be stored at the study  site in encrypted electronic and/or paper form 
and will be password protected or secured in a locked room to ensure that only authorized 
study staff have access.  The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of disaster.  In the event of a potential personal data breach,  the study site shall  be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law. 
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, when study data are compiled for transfer to Pfizer and other authorized parties, patient names will be removed and will be replaced by a single, specific, numerical code, based  on a numbering system  defined  by Pfizer.  All other  identifiable  data transferred 
to Pfizer or other authorized parties will be identified by this single, patient- specific code.  
The investigator site will maintain  a confidential list of patients  who participated  in the study, 
linking each patient’s numerical code to his or her actual identity.  In case of data transfer, 
Pfizer  will maintain  high standards of confidentiality  and protection of patients’  personal data 
consistent with the clinical study agreement and applicable privacy laws.  
10.2. Patient  Consent  
The informed consent/assent documents and any patient recruitment materials must be in compliance with local  regulatory  requirements  and legal  requirements,  including applicable 
privacy laws. 
The informed  consent/assent  documents used during the informed  consent process and any 
patient recruitment materials must be reviewed and approved by Pfizer, approved by the 
institutional review board (IRB)/independent ethics committee (IEC) before use, and available for inspection.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  32  
 The investigator must ensure that each study patient, or his/her legally acceptable 
representative, is fully informed about the nature and objectives of the study, the sharing of data relating to the study and possible risks associated with participation, including the risks associated with the processing of the patient’s personal data.  The investigator further must 
ensure that each study patient, or his or her legally acceptable representative, is fully informed  about his or her right to access and correct  his or her personal data and to withdraw 
consent for the processing of his or her personal data.  
Whenever  consent is obtained from a patient’s  legally  acceptable representative,  the patient’s 
assent (affirmative agreement) must subsequently be obtained when the patient has the capacity  to provide assent,  as determined  by the IRB/IEC.  If the investigator determines  that 
a patient’s decisional capacity is so limited that he or she cannot reasonably be consulted, then, as permitted by the IRB/IEC and consistent with local regulatory and legal requirements, the patient’s assent may be waived with source documentation of the reason assent was not obtained.  If the study patient does not provide his or her own consent, the 
source documents must record why the patient did not provide consent (eg, minor, decisionally impaired adult), how the investigator determined that the person signing the consent was the patient’s legally acceptable representative, the consent signer’s relationship to the study patient  (eg, parent, spouse),  and that the patient’s  assent  was obtained or waived. 
If assent is obtained verbally, it must be documented in the source documents.  
The investigator,  or a person designated  by the investigator,  will obtain  written  informed 
consent from each patient or the patient’s legally acceptable representative before any  
study- specific activity  is performed. The investigator will retain  the original of each patient's 
signed consent/assent document. 
10.2.1. Participation  in Investigational Clinical  Trials  
If a patient in Spain elects to participate in a double -blind or open- label interventional trial, 
entry of data into THAOS will be prohibited from the date patient begins taking study drug 
(or device) until the end of the interventional trial. Data  collected  prior  to a patient receiving 
treatment in a double -blind or open- label interventional trial (eg, baseline, pre -treatment 
assessments, or any historical data) can be entered into the THAOS electronic data record/database and data collection can resume after completion of the interventional trial.  
Data  collected  during the time of participation  in an interventional trial may not be entered 
into THAOS  
For patients enrolled outside of Spain, if a patient elects to participate in a double- blind 
investigational clinical  trial, collection  of THAOS  data will be temporarily  suspended during 
the period that the patient is taking study drug (or device). 
Data collected prior to a patient receiving treatment in a double -blind investigational trial 
(eg, baseline, pre- treatment assessments, or any historical data), as well as data collected 
after the patient’s completion or withdrawal from a double -blind investigational trial, can be 
entered  into the THAOS  electronic  data record/database.  Data  collected  during the course of 
the clinical trial may  be entered retrospectively  at the end of the trial if the THAOS principal 
investigator obtains and documents approval from the study sponsor who conducted the 
clinical trial.  Retrospective data entry cannot occur until the study has been unblinded, 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  33  
 which  will permit identification  of the treatment  received  during the trial. No reconciliation 
between databases will occur.  
As the goal of the survey is to document the course (or natural history) of TTR amyloidosis, 
the use of known interventions, including open- label investigational agents or devices, will 
be permitted.  For interventional clinical trials that include open -label tafamidis or other 
open-label investigational products, patients may continue in THAOS, with the approval of 
the Sponsor, but AE data collection  will be addressed  through the interventional clinical  trial 
sponsor. The THAOS principal investigator is responsible for obtaining and documenting 
approval from the study sponsor for investigational agents other than tafamidis.  
10.3. Patient  Withdrawal  
Patients may withdraw from the study at any time at their own request, or they may be 
withdrawn  at any time at the discretion  of the investigator  or sponsor for safety,  behavioral, 
or administrative reasons.  In any circumstance, every effort should be made to document 
patient outcome, if applicable. The investigator would inquire about the reason for withdrawal and follow -up with the patient regarding any unresolved AEs. 
Whenever possible, the patient should return for a final visit and the reason for withdrawal recorded.  If a patient does not return for further assessments and no longer wishes to 
participate in THAOS, the reason the patient provides for discontinuation from the survey will be recorded. In the event that a patient does not complete an annual visit, can no longer be contacted  within  one year of a scheduled  annual visit,  and the patient’s  status is unknown, 
the patient will be considered lost to follow -up and the principal investigator (PI) will be 
required to change the patient status in that individual’s THAOS clinical database accordingly.  
If the patient  withdraws  from the study  and also withdraws  consent  for disclosure of future 
information, no further evaluations should be performed, and no additional data should be collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent.  
10.4. Institutional Review  Board (IRB)/Independent  Ethics  Committee  (IEC)  
It is the responsibility  of the investigator to  have prospective approval of the  study protocol, 
protocol amendments, and informed consent forms, and other relevant documents, (eg, recruitment advertisements), if applicable, from the IRB/IEC.  All correspondence with 
the IRB/IEC  should be retained  by the investigator. Copies of IRB/IEC  approvals should be 
forwarded to Pfizer.  
10.5. Ethical Conduct of the  Study  
The study will be conducted in accordance with legal  and regulatory  requirements,  as well as 
with scientific purpose, value and rigor and follow generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), International Ethical Guidelines for Epidemiological Research issued by the Council for International Organizations of Medical Sciences (CIOMS), EMA European 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  34  
 Network  of Centres for Pharmacoepidemiology and Pharmacovigilance ( ENCePP)  Guide on 
Methodological Standards in Pharmacoepidemiology, and Food and Drug Administration 
(FDA) Guidance for Industry: Good Pharmacovigilance and Pharmacoepidemiologic 
Assessment, FDA Guidance for Industry  and FDA Staff: Best Practices for Conducting and 
Reporting of Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data, Guidance for Industry: Patient- Reported Outcome Measures: Use in Medical Product 
Development to Support Labeling Claims. 
11. MANAGEMENT AND REPORTING  OF ADVERSE EVENTS/ADVERSE 
REACTIONS FOR TAFAMIDIS -TREATED SUBJECTS  
11.1. Requirements  
The table below summarizes the requirements for recording safety events in the THAOS 
electronic data record and for reporting safety events on the non-interventional study (NIS) adverse event monitoring (AEM) Report Form to Pfizer Safety.  These requirements are 
delineated for 3 types of events: (1) serious adverse events (SAEs); (2) non -serious AEs (as 
applicable); and (3) scenarios involving drug exposure, including  exposure during pregnancy 
(EDP), exposure during breast feeding, medication error, overdose, misuse, extravasation, and occupational exposure. These events are defined in the section “Definitions of Safety  
Events ” 
 
Safety event  Recorded  in the THAOS 
electronic data record  Reported on the NIS 
AEM  Report  Form  to 
Pfizer Safety within 
24 hours  of awareness  
SAE All All 
Non-serious  AE All None  
Scenarios  involving  exposure 
to a drug under study, 
including EDP, exposure 
during breastfeeding, 
medication error, overdose, 
misuse,  extravasation;  lack of 
efficacy; and occupational 
exposure  All (regardless  of whether 
associated with an AE), 
except occupational 
exposure  All (regardless of 
whether associated  with 
an AE)  
 
For each AE, the investigator must  pursue and obtain information  adequate both to determine 
the outcome of the AE and to assess whether it meets the criteria for classification as a SAE (see section " Serious Adverse Events ” below). 
Safety events listed in the table above must be reported to Pfizer within 24 hours of awareness  of the event  by the investigator regardless of whether  the event  is determined 
by the investigator to be related to tafamidis.  In particular if the SAE is fatal or  
life-threatening,  notification  to Pfizer  or its designated  representative must  be made 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  35  
 immediately, irrespective of the extent of available event information.  This timeframe also 
applies to additional new (follow -up) information on previously forwarded safety event 
reports. In the rare situation  that the investigator does not become immediately  aware of the 
occurrence of a safety event, the investigator must report the event within 24 hours after 
learning of it and document the time of his/her first awareness of the events.  
For safety events that are considered serious, or that are identified in the far -right column of 
the table above, that are reportable to Pfizer within 24 hours of awareness, the investigator is obligated to pursue and to provide any additional information to Pfizer in accordance with this 24- hour timeframe.  In addition, an investigator may be requested by Pfizer to obtain 
specific follow -up information in an expedited fashion. This information is more detailed 
than that recorded in the THAOS electronic clinical database . In general, this will include a 
description of the AE in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality.  Any information relevant to the 
event, such as concomitant medications and illnesses must be provided. In the case of a 
patient  death, a summary  of available autopsy findings must be submitted  as soon as possible 
to Pfizer or its designated representative.  
11.2. Reporting  Period  
For each patient, the safety  event reporting  period  begins at the time of the patient’s  first dose 
of tafamidis or the time of the patient’s informed consent if s/he is being treated with tafamidis at study start and lasts through the end of the observation period of the study, which must include at least 28 calendar days following the last administration of a drug under study; a report must be submitted to Pfizer Safety (or its designated representative) for any of the types of safety events listed in the table above occurring during this period. 
If a patient was administered  a drug under study on the last day of the observation period, 
then the reporting period should be extended for 28 calendar days following the end of 
observation.  
Most often, the date of informed consent is the same as the date of enrollment.  In some 
situations,  there  may be a lag between  the dates of informed  consent  and enrollment.  In these 
instances,  if a patient  provides informed  consent but is never enrolled in the study (eg, patient 
changes his/her mind about participation), the reporting period ends on the date of the decision to not enroll the patient.  
If the investigator becomes aware of a SAE occurring at any time after completion of the study and s/he considers the SAE  to be related  to tafamidis,  the SAE  also must be reported  to 
Pfizer Safety.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  36  
 11.3. Causality Assessment  
The investigator is required  to assess  and record  the causal  relationship.  
For all AEs,  sufficient  information  should be obtained by the investigator to determine  the 
causality of each AE.  For AEs with a causal relationship to tafamidis, follow -up by the 
investigator is required until the event and/or its sequelae resolve or stabilize at a level 
acceptable to the investigator, and Pfizer concurs with that assessment.  
An investigator’s causality assessment is the determination of whether there exists a reasonable possibility that tafamidis caused or contributed to an AE.  If the investigator’s 
final determination of causality is “unknown” and the investigator cannot determine whether tafamidis  caused  the event, then the event will be handled as related  to tafamidis  for reporting 
purposes and the safety event must be reported within 24 hours. 
If the investigator cannot determine  the etiology of the event but the investigator determines 
that tafamidis did not cause the event, this should be clearly documented in the THAOS 
electronic clinical database and the NIS AEM Report Form.  
11.4. Definitions  of Safety  Events  
11.4.1. Adverse Events  
An AE is any untoward medical  occurrence  in a patient  administered  a medicinal  product. 
The event need not necessarily have a causal relationship with the product treatment or usage.  Examples of AEs include but are not limited to:  
• Abnormal test findings (see below for circumstances in which  an abnormal test 
finding constitutes an AE);  
• Clinically  significant symptoms and signs;  
• Changes in physical examination  findings;  
• Hypersensitivity; 
• Progression/worsening of underlying disease;  
• Lack of efficacy;  
• Drug  abuse;  
• Drug dependency.  
Additionally,  for medicinal products, they may include the signs  or symptoms resulting  from: 
• Drug  overdose;  
• Drug  withdrawal;  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  37  
 • Drug misuse;  
• Off-label  use; 
• Drug interactions;  
• Extravasation;  
• EDP;  
• Exposure during breast  feeding;  
• Medication  error; 
• Occupational exposure.  
11.4.2. Abnormal  Test Findings  
The criteria  for determining  whether an abnormal objective  test finding should be reported  as 
an AE are as follows:  
• Test result  is associated  with accompanying  symptoms, and/or  
• Test result  requires additional diagnostic  testing  or medical/surgical intervention, 
and/or  
• Test result  leads to a change in study dosing or discontinuation  from the study, 
significant additional concomitant drug treatment, or other therapy, and/or  
• Test result is  considered to be an AE by the investigator or sponsor.  
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE. Any abnormal test result  that is determined  to be an error does not require 
reporting as an AE. 
11.4.3. Serious  Adverse Events  
A SAE  is any untoward medical  occurrence in a patient  administered  a medicinal  or 
nutritional product (including pediatric formulas) at any dose that: 
• Results in death;  
• Is life-threatening  (immediate  risk of death);  
• Requires inpatient hospitalization  or prolongation of hospitalization  (see below  for 
circumstances that do not constitute AEs);  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  38  
 • Results in persistent  or significant disability/incapacity  (substantial disruption  of the 
ability to conduct normal life functions);  
• Results in congenital anomaly/birth  defect.  
Medical  and scientific  judgment is exercised  in determining  whether an event  is an important 
medical event.  An important medical event may not be immediately life -threatening and/or 
result in death or hospitalization. However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes listed in the 
definition above, the important medical event should be reported as serious.  
Examples of such events are intensive treatment in an emergency room or at home for 
allergic  bronchospasm; blood dyscrasias or convulsions that do not result  in hospitalization; 
or development of drug dependency or drug abuse. 
Additionally, any suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non- pathogenic, is considered serious.  The event may be suspected from 
clinical symptoms or laboratory findings indicating an infection in a patient exposed to a Pfizer product.  The terms “suspected transmission” and “transmission” are considered 
synonymous. These cases are considered  unexpected and handled as serious  expedited cases 
by pharmacovigilance personnel. Such cases are also considered for reporting as product 
defects, if appropriate.  
11.5. Hospitalization  
Hospitalization is defined as any initial admission (even if less than 24 hours) to a hospital or 
equivalent healthcare facility or any prolongation to an existing admission. Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric wing to a medical floor, medical floor to a coronary care unit, neurological floor to a tuberculosis unit).  An emergency  room  visit does not necessarily  constitute a hospitalization; 
however, an event leading to an emergency room visit should be assessed for medical importance.  
Hospitalization  in the absence of a medical  AE is not in itself an AE and is not reportable. 
For example, the following reports of hospitalization without a medical AE are not to be reported:  
• Social  admission (eg, patient/subject has no place  to sleep);  
• Administrative  admission  (eg, for yearly  exam);  
• Optional admission  not associated  with a precipitating  medical  AE (eg, for elective 
cosmetic surgery);  
• Hospitalization  for observation without a medical  AE; 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  39  
 • Admission for treatment of a pre -existing condition not associated with the 
development of a new AE or with a worsening of the pre- existing  condition (eg, for 
work -up of persistent pre- treatment lab abnormality); 
• Protocol- specified  admission  during clinical  study  (eg, for a procedure required  by 
the study protocol). 
11.6. Scenarios Necessitating  Reporting  to Pfizer  Safety  within  24 Hours  
Scenarios involving exposure during pregnancy, exposure during breastfeeding, medication 
error, overdose, misuse, extravasation, lack of efficacy, and occupational exposure are described below. 
11.6.1. Exposure  During Pregnancy  
1. An exposure during pregnancy (EDP) occurs if a female becomes, or is found to be, 
pregnant either  while  receiving or having been  directly  exposed to (eg, environmental 
exposure) tafamidis, or the female becomes, or is found to be, pregnant after discontinuing and/or being directly exposed to tafamidis (maternal exposure). 
2. An example of environmental exposure would be a case involving direct  contact with 
a Pfizer product in  a pregnant woman  (eg, a nurse reports that  she is  pregnant and has 
been exposed to chemotherapeutic products). 
As a general rule, prospective and retrospective EDP reports from any source are reportable irrespective  of the presence  of an associated  AE and the procedures for SAE  reporting  should 
be followed. 
If a study participant becomes, or is found to be, pregnant during the study participant’s 
treatment with tafamidis, this information must be submitted to Pfizer, irrespective of whether an adverse event has occurred, using the NIS AEM Report Form and the EDP Supplemental Form, and through the Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO).  Reporting to TESPO  for women  exposed to tafamidis  will also include 
a 6-month and 12-month post- birth follow -up questionnaire regarding developmental 
milestones.  
In addition, the information regarding environmental exposure to tafamidis in a pregnant woman  (eg, a patient  reports  that she is pregnant and has been  exposed to a cytotoxic product 
by inhalation or spillage) must be submitted using the NIS AEM Report Form and the EDP supplemental form. This must be done irrespective of whether an AE has occurred. 
Information  submitted  should include the anticipated  date of delivery  (see below for 
information related to termination of pregnancy).  
Follow- up is conducted to obtain general information on the pregnancy; in addition, 
follow -up is conducted to obtain information  on EDP  outcome for all EDP  reports  with 
pregnancy o
utcome unknown. A pregnancy is followed until completion or until pregnancy 
termination  (eg, induced abortion) and Pfizer  is notified  of the outcome. This information  is 
provided as a follow up to the initial EDP report. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  40  
 In the case of a live birth,  the structural  integrity  of the neonate can be assessed  at the time of 
birth.  In the event of a termination, the reason(s) for termination should be specified and, if 
clinically  possible,  the structural  integrity  of the terminated  fetus  should be assessed  by gross 
visual inspection (unless pre -procedure test findings are conclusive for a congenital anomaly 
and the findings are reported). 
If the outcome of the pregnancy meets the criteria for an SAE (eg, ectopic pregnancy, 
spontaneous abortion, intrauterine  fetal demise,  neonatal death, or congenital anomaly [in a 
live born, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the procedures for reporting SAEs should be followed. 
Additional information about pregnancy outcomes that are reported as SAEs follows: 
• Spontaneous abortion includes miscarriage  and missed  abortion;  
• Neonatal  deaths that occur within  1 month of birth  should be reported, without regard 
to causality, as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to investigational product. 
Additional information  regarding the EDP  may be requested.  Further follow -up of birth 
outcomes will be handled on a case-by- case basis (eg, follow -up on preterm infants to 
identify developmental delays).  
11.6.2. Exposure  During  Breastfeeding  
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated  AE. An exposure during breastfeeding  report is not created  when  a Pfizer drug 
specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord  with authorized use. However,  if the infant experiences an AE associated  with such a 
drug’s administration, the AE is reported together with the exposure during breastfeeding. 
11.6.3. Medication  Error  
A medication error is any unintentional error in the prescribing, dispensing or administration 
of a medicinal  product that may cause or lead to inappropriate medication  use or patient  harm 
while in the control of the health care professional, patient, or consumer. Such events may  
be related to professional practice, health care products, procedures, and systems including: prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use. 
Medication  errors  include:  
• Near  misses,  involving or not involving a patient directly  (eg, inadvertent/erroneous 
administration, which is the accidental use of a product outside of labeling or 
prescription on the part of the healthcare provider or the patient/consumer);  
• Confusion with regard  to invented name  (eg, trade  name,  brand name).  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  41  
 The investigator must  submit the following  medication  errors  to Pfizer within  24 hours of 
awareness, irrespective of the presence of an associated AE/SAE:  
• Medication  errors  involving patient  exposure to the product, whether or not the 
medication error is accompanied by an AE. 
• Medication errors including potential medication errors or near misses that do not 
involve a patient directly.  When  a medication  error  does not involve patient exposure 
to the product the following minimum criteria constitute a medication error report:  
• An identifiable  reporter; 
• A suspect  product;  
• The event medication  error.  
11.6.4. Overdose,  Misuse,  Extravasation  
Reports of overdose, misuse,  and extravasation  associated  with the use of a Pfizer  product are 
reported to Pfizer by the investigator, irrespective of the presence of an associated AE/SAE.  
11.6.5. Lack  of Efficacy  
Reports of lack of efficacy to a Pfizer product are reported to Pfizer by the investigator, irrespective  of the presence of an associated  AE/SAE  or the indication for use of the Pfizer 
product.  
11.6.6. Occupational Exposure  
Reports of occupational exposure to a Pfizer  product are reported  to Pfizer by the 
investigator, irrespective of the presence of an associated AE/SAE.  
11.7. Single  Reference Safety  Document  
The Core  Data Sheet  will serve as the single reference  safety  document during the course of 
the study, which will be used by Pfizer safety to assess any safety events reported to Pfizer Safety by the investigator during the course of this study. 
The Product Label  should continue to be used by the investigator for prescribing  purposes 
and guidance. 
12. PLANS  FOR  DISSEMINATING  AND COMMUNICATING  STUDY RESULTS  
12.1. Communication  and Publication  of Study  Results  
In the event of any prohibition or restriction  imposed  (eg, All information  in the protocol and 
other documents provided to the survey physician and survey team are privileged and 
confidential information.  The physician will use this information to accomplish the survey 
and will not use it for publication  without written  consent from  the Sponsor. It is understood 
that the survey physician has agreed to provide the Sponsor with data obtained during the survey. The information obtained from the survey may be disclosed to regulatory authority(ies), other investigators, or other parties identified by the Sponsor. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  42  
 It is anticipated that the survey results will be presented at scientific meetings and/or 
published in peer-reviewed  scientific  or medical  journals. The Scientific  Board  will oversee 
publication of pooled survey results, which will reflect the experience of all participating centers  
The Sponsor will retain  legal  ownership of all data collected  from  all sites that participate  in 
the survey. Data from each participating site is the property of that participating site.  Each 
participating  physician is  free to use and publish his or her own data in compliance with the 
agreement with the Sponsor. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  43  
 13. References  
1. Connelly S, Choi S, Johnson SM, et al. Structure  based  design  of kinetic  stabilizers  that 
ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 2010; 20(1):54-62. 
2. Klabunde T, Petrassi  HM, Oza VB, et al. Rational  design of potent human  transthyretin 
amyloid disease inhibitors. Nat Struct Biol 2000; 7(4):312 -21. 
3. Johnson SM, Wiseman  RL, Sekijima  Y, et al. Native  state kinetic stabilization  as a 
strategy to ameliorate protein misfolding diseases: A focus on the transthyretin 
amyloidoses. Acc Chem Res 2005; 38(12):911- 21. 
4. Sekijima,  Y., Ueda,  M., Koike, H.  et al. Diagnosis and management  of transthyretin 
familial amyloid polyneuropathy  in Japan: red-flag symptom clusters  and treatment 
algorithm. Orphanet J Rare Dis 13, 6 (2018) doi:10.1186/s13023-017-0726-x. 
5. Gavrin  LK, Denny A, Saiah  E. Small Molecules  that Target  Protein  Misfolding.  J Med 
Chem. 2012;55(24):10823-43. 
6. Adams D, Suhr O, et al. First European consensus for diagnosis, management, and treatment of transthyretin  familial  amyloid polyneuropathy. Curr Opin  Neurol 2016, 29 
(suppl 1):S14–S26. 
7. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin- related hereditary 
amyloidosis  for clinicians.  Orphanet J Rare  Dis 8, 31 (2013) doi:10.1186/1750-1172-8- 
31. 
8. Ando Y, Nakamura M, Araki  S. Transthyretin -related  familial amyloidotic 
polyneuropathy. Arch Neurol. 2005; 62:1057-1062. 
9. Adams  D. Hereditary  and acquired  amyloid  neuropathies. J Neurol. 2001; 248:647- 657. 
10. Lobato L. Portuguese- type amyloidosis  (transthyretin  amyloidosis, ATTR  V30M). J. 
Nephrol. 2003; 16:438-442. 
11. Waddington Cruz  M, Schmidt H, et al. Epidemiological and clinical  characteristics  of 
symptomatic hereditary transthyretin amyloid polyneuropathy: A global case series. Orphanet J Rare Dis. 2019;14(1):34. 
12. Conceicao  I, Coelho T,  et al. Assessment  of patients  with  hereditary  transthyretin 
amyloidosis – understanding the impact of management and disease progression. 
Amyloid. 2019;26(3):103-111. 
13. S
harma  P, Perri RE,  Sirven  JE, et al. Outcome of liver transplantation  for familial 
amyloidotic polyneuropathy. Liver Transpl. 2003; 9:1273-1280. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  44  
 14. Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for 
transthyretin  amyloidosis: follow-up of Japanese familial amyloidotic  polyneuropathy 
patients. J. Neurol. Sci. 1999; 171:19-23. 
15. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation  for familial amyloidotic  polyneuropathy: results 
from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004; 77:64-71. 
16. Adams  D, Gonzalez -Duarte  A, O'Riordan WD,  et al. Patisiran,  an RNAi  therapeutic,  for 
hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11-21. 
17. Buxbaum JN. Oligonucleotide drugs for transthyretin  amyloidosis.  N Engl J Med 
2018;379:82 -85. 
18. Benson MD, Waddington- Cruz  M, Berk  JL, et al. Inotersen  treatment  for patients  with 
hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22-31. 
19. Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin  type familial amyloid  polyneuropathy. Amyloid. 
2003; 10: 229-239. 
20. Ruberg FL, Berk  JL. Transthyretin  (TTR)  cardiac amyloidosis.  Circulation  2012; 126: 
1286- 300. 
21. Rapezzi  C, Quarta  CC, Riva  L, et al. Transthyretin -related  amyloidoses and the heart:  a 
clinical overview. Nat Rev Cardiol 2010; 7: 398-408. 
22. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant sequence transthyretin (isoleucine 122) in late onset cardiac  amyloidosis  in black  Americans.  NEJM  1997; 
336:466- 73. 
23. Westermark P, Sletten K, Johansson B, Cornwell, III GG. Fibril in senile systemic amyloidosis  is derived from  normal transthyretin.  Proc.  Natl.  Acad.  Sci. 1993; 87:2843- 
2845.  
24. Pitkanen P, Westermark  P, Cornwell,  III GG. Senile  systemic amyloidosis.  Am J 
Pathol. 1984; 117:391-399. 
25. Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin -derived 
senile systemic amyloidosis: clinicopathologic  and structural  considerations.  Amyloid. 
2003; 10 Suppl 1:48-54. 
26. Saraiva MJ. Transthyretin  mutations  in health  and disease.  Hum  Mutat  1995; 5(3):191 
6. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  45  
 27. Kyle  RA, Spittell PC, Gertz  MA, et al. The premortem recognition of systemic  senile 
amyloidosis with cardiac involvement. Am. J. Med. 1996; 101:395-400. 
28. Witteles R, Bokhari S, Damy T, et al. Screening for transthyretin amyloid 
cardiomyopathy in everyday practice.  JACC Heart  Fail. 2019;7(8):709-716. 
29. Hutt D, Fontana M, Burniston, et al. Prognostic utility  of the Perugini grading of 99m 
Tc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with 
skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1344-1350. Doi: 10.1093/ehjci/jew325. 
30. Maurer  MS, Schwartz,  JH, Gundapaneni B, et al. Tafamidis  treatment  for patients  with 
transthyretin amyloid cardiomyopathy. N Engl J Med. 2018; 379;1007-1016. 
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  46  
  
 
14. LIST OF TABLES  
Table  1. Summary  of Safety  Concerns to be Assessed  in THAOS  ......................... 26 
15. LIST OF FIGURES  
None.  
ANNEX 1. LIST OF STAND- ALONE DOCUMENTS  
None.  
ANNEX  2. ENCEPP  CHECKLIST FOR  STUDY  PROTOCOLS  
This annex is not required.  
ANNEX 3. ADDITIONAL INFORMATION  
See Patient  Reported Outcome Questionnaires below.  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
CCI  
PFIZER  CONFIDENTIAL  
Page  47  
 
 
  
 
CCI  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
CCI  
PFIZER  CONFIDENTIAL  
Page  48  
 C 
 
   
 
CCI  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
CCI  
PFIZER  CONFIDENTIAL  
Page  49  
  
 
CCI  
PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
CCI  
PFIZER  CONFIDENTIAL  
Page  50  
  
 

PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  51  
  
 
 

PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  52  
  
  
 
 
 

PF-06291826,  Tafamidis  meglumine  
B3461001  NON -INTERVENTIONAL  STUDY  PROTOCOL  
Final  Protocol  Amendment  5, 13 July 2020  
PFIZER  CONFIDENTIAL  
Page  53  
  
 

 
 Signed By: Date(GMT)  Signing Capacity   
Document Approval Record 
 
 
B3461001 Non-lnterventional  Protocol  Amendment  5 (clean)_13 July 2 
020 
 
B3461001 Non-lnterventional  Protocol  Amendment  5 (clean)_13 July 2 
020 
 
 
PPD  
PPD   16-J ul -2020 12:39:30  Business  Line Approver  
 
16-Jul-2020 21:49:21  EUQPPV Approval  Document Name:  
 
 
Document Title:  